Veracyte, Inc. (VCYT) fair value analysis

Nasdaq · Updated 2026-09-07

Veracyte, Inc. is a diagnostics company that develops and commercializes molecular tests used to help clinicians make clinical decisions for patients with cancer and other diseases. The company operates primarily in the United States and serves healthcare providers and patients through its laboratory and testing services.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, VCYT is trading at within about 10% of estimated fair value.

VCYT currently ranks #84 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $44.85
Sector: Healthcare
12-month range: $32.40–$59.85

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for VCYT

Our model validated 7 trailing price-to-earnings windows for VCYT, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $32.40–$59.85.
The 14-day relative strength index sits at a neutral 41.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for VCYT
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent VCYT news

TickrTrends' derived news-sentiment signal for VCYT is currently leaning positive, computed from recent coverage.

Veracyte Inc (VCYT) Shares Fall 4.8% -- GF Value Says Still Overvalued (gurufocus.com, 2026-09-05)
TickrTrends take: Veracyte's recent share decline occurs within a context where TickrTrends currently assesses the stock as fairly valued, creating a divergence with the GF Value perspective cited in the headline. For investors focused on valuation metrics, this disagreement between different valuation approaches suggests monitoring how the stock's fundamental metrics and market conditions evolve before drawing conclusions about its true value relative to peers in the Healthcare sector. The fair value assessment from TickrTrends indicates the market may be pricing in reasonable expectations for the company at present levels.
Veracyte (VCYT) Director Muna Bhanji Sells 1,864 Shares (gurufocus.com, 2026-09-04)
TickrTrends take: A director's sale of shares can signal management's views on valuation, though insider transactions are often executed for personal financial planning rather than as commentary on company value. Given TickrTrends' assessment of VCYT as fairly valued within the Healthcare sector, readers tracking the stock should monitor whether additional insider activity or changes in fundamental metrics emerge that might alter this valuation perspective. The sale's timing and the director's remaining shareholding position could provide context for interpreting management's confidence levels in the company's near-term prospects.
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors (gurufocus.com, 2026-09-02)
TickrTrends take: Veracyte Inc trades in the Healthcare sector where valuation metrics carry particular weight given the sector's sensitivity to clinical outcomes and regulatory developments. The company's GF Score of 81 indicates strong fundamental quality across multiple dimensions, which aligns with TickrTrends' current assessment that the stock is Fairly valued. For valuation-focused readers, the key consideration is whether this quality score will support the current price level if near-term clinical or commercial catalysts shift, or if the market's confidence in those fundamentals may adjust the valuation multiple in either direction.

What people are saying

Follow the VCYT conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is VCYT stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), VCYT is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is VCYT's TickrTrends verdict?

VCYT's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does VCYT compare to other Healthcare stocks?

VCYT ranks #84 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is VCYT overbought or oversold?

VCYT's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

VCYT vs ABBV · VCYT vs BIIB · VCYT vs BIO · VCYT vs BVS · VCYT vs JAZZ